Tumor marker ca125 in ovarian cancer

Journal of Tumor Marker Oncology

Volumn 16, Issue 1, 2001, Pages 49-68

  Tuxen, Malgorzata K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0009295174     PISSN: 08863849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (151)

1. Storm HH, Pihl J, Michelsen E, Nielsen AL. Cancer incidence in Denmark 1993. 1993. Danish Cancer Society.
2. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 71: 5 17-523.
3. Ozols RF, Vermorken JB: Chemotherapy of advanced ovarian cancer: current status and future directions. Sem Oncol 1997; 24: S2-1-S2-9.
4. Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasrnussen K: Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990; 37: 279-283.
5. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337.
6. Bast RC, Jr., Kiug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engi J Med 1983; 309: 883-887.
7. Kabawat SE, Bast RC, Jr., Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomicepitheliurn-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 1983; 2: 275285.
8. Dietel M, Arps H, Klapdor R, MullerHagan 5, Sieck M, Hoffmann L: Antigen detection by monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patient's sera. J Cancer Res Clin Oncol 1986; 111:257-265.
9. Nouwen EJ, Follet DE, Eerdekens MW, Hendrix PG, Briers TW, De Bro ME: Immunohistochemical localization of placenta! alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 1986; 46: 866-876.
10. Molina R, Ballesta AM, Casals E, Borras G, Elena M, Balaue A: Value of CA 125 antigen as tumour marker: preliminary results. Protides Biol Fluids 1984; 32: 613-616.
11. Grover S, Quinn MA, Weidernan P, et al: Screening for ovarian cancer using serum CA 125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995; 5: 291295.
12. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80: 14-18.
13. Zurawski VR, Jr., Sjovall K, Schoenfeld DA, et al: Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990; 36: 299305.
14. Zurawski VR, Jr., Broderick SF, Pickens P, Knapp RC, Bast RC, Jr.: Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 1987; 69: 606-611.
15. Cane P, Azen C, Lopez E, Platt LD, Karlan BY: Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovariaii cancer screening. Gynecol Oncol 1995;57:240-245.
16. Kan YY, Yeh SH, Ng HT, Lou CM: Effect of menstruation on serum CA 125 levels. Asia-Oceania J Obstet Gynaecol 1992; 18: 339-343.
17. Lehtovirta P, Apter D, Stenman UH: Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol 1990; 97: 930-933.
18. Mastropolo W, Fernandez Z, Miller EL: Pronounced increases in the concentration of an ovarian tumor marker, CA 125, in serum of a healthy subject during menstruation. Clin Chem 1986:32:2110-2111.
19. Haga Y, Sakamoto K, Egami H, Yoshirnura R, Akagi M: Evaluation of serum CA 125 values in healthy individuals and pregnant women. Am JMedSd 1986:292:25-29.
20. Brumsted JR, Nakajima ST, Badger G, Riddick DH, Gibson M: Serum concentration of CA-125 during the first trimester of normal and abnormal pregnancies. J Reprod Med 1990; 35: 499-502.
21. Predictive values for monitoring healthy subjects and patients. In: Statistical bases of reference values in laboratory medicine. Harris EK,
22. Boyd JC, eds. New York: Marcel Dekkerlnc., 1995; 22 1-258.
23. Koper NP, Thomas CMC, Massuger LFAG, van der Mooren MJ, Kiemeney LALM, Verbeek ALM: Serum CA 125 concentrations in women of different ages, hormonal status, or clinical conditions. Int J Gynecol Cancer 1997:7:405-411.
24. Buarnah PK, Skillen AW: Serum CA 125 concentrations in patients with benign ovarian tumours. J Surg Oncol 1994:56:71-74.
25. Mozas J, Castilla JA, Jimena P, Gil T, Acebal M, Herruzo AJ: Serum CA-125 in the diagnosis of acute pelvic inflammatory disease. Tnt J Gynaecol Obstet 1994; 44: 53-57.
26. Patton PE, Field CS, Harms RW, Coulam CB : CA-125 levels in endometriosis. Fertil Steril 1986;45: 770-773.
27. Moloney MD, Thornton JG, Cooper EH: Serum CA 125 antigen levels and disease severity in patients with endometriosis. Obstet Gynecol 1989; 73: 767-769.
28. Ruibal A, Encabo G, Martinez-Miralles E, et al: CA 125 série levels in noii malignant pathologies. Bull Cancer 1984:71:145-146.
29. Molina R, Filella X, Bruix J, et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 37: 13791383.
30. Collazos J, Genolla J, Ruibal A: CA 125 serum levels in patients with nonneoplastic liver diseases. A clinical and laboratory study. Scand J Clin Lab Invest 1992; 52:20 1-206.
31. Collazos J, Diaz F: Cancer antigen 125 in patients with liver diseases. Clin Chem 1992; 38: 1188-1189.
32. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW: CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986; 155: 1097-1102.
33. Markowska J, Kojczynski Z, Szewierski Z, Manys G: CA 125 in monitoring chemotherapy of the patients with ovarian cancer. Eur J Gynaecol Oncol 1990; 11: 209-214.
34. Tholander B, Taube A, Lindgren A, Sjoberg 0, Stendahl U, Tamsen L: Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990; 39: 2633.
35. Panza N, Pacilio G, Campanella L, et al: Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and betachain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer 1988; 61: 76-83.
36. Kudlacek 5, Schieder K, Kolbl H, et al: Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer. Gynecol Oncol 1989; 35: 323329.
37. Hurteau JA, Woolas RP, Jacobs U, et al: Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995:76:1615-1620.
38. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V: Preoperative evaluation of D-dimer and CA 125 levels in differeiitiatiiig benign from malignant ovarian masses. Gynecol Oncol 1996; 60: 197-202.
39. Latimer JA, Beng CG, Davy MU: For stage III epithelial ovarian cancer the initial level of expression of CA 125 does not correlate with survival in women who respond to treatment. Int J Gynecol Cancer 1996; 6: 380-3 84.
40. Gonzalez A, Vizoso F, Vâzquez J, Ruibal A, Balibrea JL: Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma. Int J Biol Markers 1997; 12: 112-117.
41. Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765769.
42. Bruzzone M, Onetto M, Campora E, et al: CA-125 monitoring in the management of ovarian cancer. Anticancer Res 1990; 10: 1353-1359.
43. Vergüte TB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K: CA 125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumor Biol 1992; 13:168-174.
44. Hording U, Toftager-Larsen K, Dreisler A, et al: CA 125, placental alkaline phosphatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers. Gynecol Obstet Invest 1990; 30: 178183.
45. Fisken J, Leonard RC, Badley A, et al: Serological monitoring of epithelial ovarian cancer. Dis Markers 1991; 9: 175-190.
46. Hising C, Anjegard TM, Einhorn N: Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol 1991; 14: 111-114.
47. Devine PL, McGuckin MA, Quin RJ, Ward BG : Predictive value of the combiation of serum markers, CA 125, CASA and TPS in ovariaii cancer. Int J Gynecol Cancer 1995; 5: 170-178.
48. Zurawski VR, Jr., Knapp RC, Einhorn N, et al: An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988; 30: 7-14.
49. But I, Gorisek B: Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol Oncol 1996; 63: 166-172.
50. Toftager-Larsen K, Hording U, Dreisler A, et al: CA-125, placental alkaline phospnatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma. Gynecol Obstet Invest 1992; 33: 177182.
51. Jacobs I, Stabile I, Bridges J, et al: Multimodal approach to screening for ovarian cancer. Lancet 1988; 1: 268271.
52. Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement aiid ultrasonography. Br Med J 1993; 306: 10SO1034.
53. Jacobs IJ, Oram DH, Bast RC, Jr.: Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992; 80: 396-399.
54. Hakama M, Stenman UH, Knekt P, et at: CA 125 as a screening test for ovarian cancer. J Med Screening 1996;3:40-42.
55. Malkasian GD, Jr., Knapp RC, Lavin PT, et al: Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341-346.
56. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP: Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988; 71: 75 1-756.
57. Patsner B, Mann WJ: The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988; 159: 873-876.
58. FinklerNJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC: Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988; 72: 659-664.
59. Antonic J, Rakar S: Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Eur J Gynaecol Oncol 1996; 17:29-35.
60. Strigini FA, Gadducci A, Del Bravo B, Ferdeghini M, Genazzani AR: Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996; 61: 6872.
61. Maggino T, Sopracordevole F, Matarese M, Di Pasquale C, Tambuscio G: CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods. Eur J Gynaecol Oncol 1987; 8:590-595.
62. Maggino T, Gadducci A, D'Addario V, et al: Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994; 54: 117-123.
63. Gadducci A, Capriello P, Bartoiini T, et al: The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. Eur J Gynaecol Oncol 1988; 9: 373-376.
64. Jacobs I, Oram D, Fairbanks J, Turner J . Frost C, Grudzinskas JG: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922-929.
65. Schutter EM, Kenemans P, Sohn C, et al: Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994; 74: 1398-1406.
66. Troiano RN, Quedens-Case C, Taylor KJ: Correlation of findings on transvaginal sonography with serum ÇA 125 levels. Am J Roentgenology 1997; 168: 1587-1590.
67. Predanic M, Vlahos N, Pennisi JA, Moukhtar M, Aleern FA: Color and pulsed Doppler sonography, grayscale imaging, and serum CA 125 in the assessment of adnexal disease. Obstet Gynecol 1996; 88: 283-288.
68. Tholander B, Taube A, Lindgren A, eta!: Pretreatment serum levels of CA125, carcinoembryonic antigen, tissue polypeptide antigen, and placenta! alkaline phosphatase in patients with ovarian carcinoma, bordeline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol 1990; 39: 16-25.
69. Tnoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa 0: Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992; 79: 434-440.
70. McGuckin MA, Ramm LE, Joy GJ, Free KE, Ward BG: Preoperative discrimination between ovarian carcinoma, non-ovarian gynecological malignancy and benigii adnexal masses using serum levels of CA 125 and the polymorphic epithehial mucin antigens CASA, OSA and MSA. Int. Cancer 1992; 2: 119-128.
71. Mogensen 0, Mogensen B, Jakobsen A: Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol 1990; 38: 170-174.
72. Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P : Comparison of tumor-associated trypsin inhibitor (TATI) with CA 125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest 1991; 51:19-24.
73. Gadducci A, Ferdeghini M, Prontera C, et al: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992; 44: 147-154.
74. Einhorn N, Knapp RC, Bast RC, Zurawski VR, Jr.: CA 125 assay used in conjunction with CA 15-3 and TAG72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 1989:28:655-657.
75. Fioretti P, Gadducci A, Ferdeghini M, Bartolini T, Fontana V, Facchini V: Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses. Eur J Gynaecol Oncol 1988; 9: 291-294.
76. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC, Jr.: Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990; 75: 249-254.
77. Woolas RP, Conaway MR, Xu F, et al: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59: 111-116.
78. Hogdalh CK, Mogensen O, Tabor A, et al: The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors. Gynecol Oncol 1995; 56: 22-28.
79. Onsrud M, Shabana A, Austgulen R: Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 1996; 17: 90-96.
80. Fioretti P, Gadducci A, Ferdeghini M, et al: Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer. Eur J Gynaecol Oncol 1986; 7: 200-205.
81. Fioretti P, Gadducci A, Ferdeghini M, Bartohini T, Bianchi R, Facchini V: Correlation of CA125 and CA 19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. Gynecol Oncol 1987:28:278-283.
82. Fioretti P, Gadducci A, Ferdeghini M, et al: The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992; 44: 155-160.
83. Cruickshank DJ, Terry PB, Fullerton WT: CA 125-response assessment in epithelial ovarian cancer. Int J Cancer 1992:51:58-61.
84. Krebs HB, Gopherud DR, Kilpatrick SJ, Myers MB, Hunt A: Role of CA 125 as tumor marker in ovarian carcinoma. Obstet Gynecol 1986; 67: 473-477.
85. Rustin GJ, Nelstrop AE, Crawford M, et al: Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA 125. J Clin Oncol 1997; 15: 172-176.
86. Rustin GJS, van der Burg MEL, Berek JS: Tumour markers. Ann Oncol 1993; 4: S71-S77.
87. Tuxen MK, Söletormos G, Petersen PH, Schioler V. Dombernowsky P: Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999; 74: 12-22.
88. Negishi Y, Furukawa T, Oka T, et al: Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Gynecol Obstet Invest 1987:23:200-207.
89. McGuckin MA, Layton GT, Bailey Mi, Hurst T, Khoo SK, Ward BG: Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovariaii carcinomacomparison with CA125. Gynecol Oncol 1990; 37: 165-171.
90. Ward BG, McGuckin MA, Ramrn LE, et al: The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays. Cancer 1993; 71: 430-438.
91. Sliutz G, Tempfer C, Kainz C, et at: Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Res 1995; 15:1127-112.
92. Rustin GJS, Nehstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study. Ann Oncol 1996; 7:36 1-3 64.
93. Alien DG, Baak J, Belpomme D, et a!: Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993; 4: S83-S88.
94. Berek JS, Brady MF, Carmichael J, et al: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10:87-92.
95. Van der Burg MEL, van Leiit M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Eng J Med 1995; 332:629-634.
96. Quaranta M, Coviello M, Donadeo A, et al: Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden aiid response to chemotherapy. Tumori 1991:77:167-169.
97. Berek JS, Knapp RC, Malkasian GD, et a!: CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 685-689.
98. Panic! PB, Scambia G, Baiocchi G, lacobelli 5, Mancuso S: Predictive value of multiple tumor marker assays in second-look procedures for ovariaii cancer. Gynecol Oncol 1989; 35: 286289.
99. Patsner B, Orr JW, Jr., Mann WJ, Jr., Taylor PT, Partridge E, Alimen T : Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990:37:319-322.
100. Mogensen 0, Mogensen B, Jakobsen A, Sell A: Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation. Eur J Cancer Clin Oncol 1988; 24: 18351837.
101. Rubin SC, Hoskins WJ, Hakes TB, et al: Serum CA 125 levels and surgical findings in patients undergoiiig secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989; 160:667-671.
102. Makar AP, Kristensen GB, Bormer OP, Trope CG: CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992; 45: 323-328.
103. Hogdall CK, Hording U, ToftagerLarsen K, Arends J, NorgaardPedersen B, Clemmensen I: Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- aiid third-look operations for ovarian cancer. Acta Oncol 1996; 35: 63-69.
104. Barrenetxea G, Martin-Mateos M, Barzazan MJ, Montoya F, Matia JC, Rodriguez-Escudero FJ: Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas. Eur J Gynaecol Oncol 1990; 11: 369-374.
105. Hording U, Toftager-Larsen K, Lund B, et a!: The value of CA 125 measurement before second-look laparotomy in patieiits with ovarian carcinoma. Eur J Gynaecol Oncol 1994; 15:217-221.
106. Mogensen 0: Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44:207-2 12.
107. Redman CW, Blackledge GR, Kelly K, Powell I, Buxton EJ, Luesley DM: Early serum CA 125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990; 26: 593-596.
108. Fisken J, Leonard RC, Stewart M, et at: The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993; 68: 140-145.
109. Makar AP, Kristensen GB, Bormer OP, Trope CG: Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993; 49: 73-79.
110. Yedema CA, Kenemans P, Voorhorst F, et al: CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993; 67: 13611367.
111. HO.Gadducci A, Zola P, Landoni F, et al: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58: 42-47.
112. Koper NP, Massuger LFAG, Thomas CMG, et al: Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer. Int J Gynecol Cancer 1997; 7: 127-133.
113. Laviii PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC, Jr.: CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987; 69: 223-227.
114. Rustin GJS, Gennings IN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD: Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989; 7: 1667-1671.
115. Frasci G, Conforti 5, Zullo F, et al: A risk model for ovarian carcinoma patients using CA 125:time to normalization renders second-look laparotomy redundant. Cancer 1996; 77: 1122-1130.
116. van der Burg ME, Lammes FB, van Putten WL, Stoter G: Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307-3 12.
117. Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de Vries EG: CA-125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer 1991; 27:993-995.
118. Hawkins RE, Roberts K, Wiltshaw E, Mundy I, Fryatt U, McCready VR: The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 13951399.
119. Högberg T, Kagedal B: Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69:423-429.
120. Hunter VJ, Daly L, Helms M, et al: The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990; 163: 1164-7.
121. Riedinger JM, Barillot I, Coudert B, Fargeot P, Berriolo-Riedinger A, Guerrin J: Prognostic value of CA 125 initial half-life measured during firstline chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV. Bull Cancer 1996; 83: 654-663.
122. Ind T, Ties R, Shepherd J, Chard T: Serum concentrations of cancer antigen 125, placenta! alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br J Obstet Gynaecol 1997; 104: 1024-1029.
123. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala 0 : Tumour-associated trypsin inhibitor (TATI): comparison with CA 125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994:70:1188-1190.
124. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG: Prognostic value of pre- and postoperative serui-n CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-1010.
125. Gard GB, Houghton CRS: An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994; 53: 283-289.
126. Ron TG, Tnbar M, Gelernter l, et at: Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994; 73: 658662.
127. Nagele F, Petru E, Mcdl M, Kainz C, GrafAH, Sevelda P: Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259-264.
128. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia P1: CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 1991; 165: 360-367.
129. Payers PM, Rustin G, Wood R, et al: The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993; 3: 285-292.
130. Mogensen O, Mogenseii B, Jakobsen A, Sell A: Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors. Acta Oncol 1989; 28: 471473.
131. Mogensen 0, Mogensen B, Jakobsen A: CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol 1989;25:1187-1190.
132. Medl M, Ogris E, Peters-Engi C, Leodolter 5: TATT (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. Br J Caiicer 1995; 71: 105 1-1054.
133. Peters-Engl C, Mcdl M, Ogris E, Leodolter S: Tumor-associated trypsin inhibitor (TATT) and cancer antigen 125 (CA 125) in patients with epithelial ovarian cancer. Anticancer Res 1995; 15:2727-2730.
134. Bhatavdekar JM, Shah NG, Trivedi SN, Karelia NH, Balar DB, Patel TB: CA 125 as a marker in epithelial ovarian cancer: Alone and in comparison with CEA. Indian J Cancer 1987; 24: 222-231.
135. Gadducci A, Ferdeghini M, Ceccariiii T, et al: The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data. J Nucl Med Allied Sci 1989; 33: 32-36.
136. Nishimura H, Tashiro M, Harnaguchi K, et al: Significance of the serum CA 125 level in recurrent ovarian cancer. Asia-Oceania J Obstet Gynaecol 1992:18:37-43.
137. Schleich HG, Hofmann T, Wischnik A, et at: On the validity of simultaneous determinations of CA125, SRA, and CA 72-4 in patients suffering from ovarian tumors. Onkologie 1993; 16: 199-203.
138. Harlozinska A, Sedlaczek P, van Dalen A, Rozdolski K, Einarsson R: TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 1997;17: 4473-4478.
139. Podnos YD, Gamboa G, Kurosaki T, Buller R, Walker JL, Manetta A: Ovarian vein vs peripheral blood CA 125 serum levels: a comparative study. Gynecol Oncol 1997; 66: 7 174.
140. Einhorn N, Bast RC, Jr., Knapp RC, Tjernberg B, Zurawski VR, Jr.: Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67:4 14-4 16.
141. Di-Xia C, Schwartz PE, Xinguo L, Zhan Y: Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988; 72: 23-27.
142. Zanetta G, Vergani P, Lissoni A: Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 1994;73:637-641.
143. Schutter EMJ, Sohn C, Kristen P, et at: Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998; 69: 56-63.
144. Alvarez RD, To A, Boots LR, et al. CA 125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 1987; 26: 284-9.
145. Vergote TB, Bormer OP, Abeler VM. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987; 157: 88-92.
146. NiloffJM, Knapp RC, Lavin PT, et al: The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986; 155: 56-60.
147. Cruickshank DJ, Terry PB, Fullerton ' WT: The potential value of CA 125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer. Int J Biol Markers 1991; 6: 247-252.
148. Markowska J, Manys G, Szewierski Z: CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study. Eur J Gynaecol Oncol 1992; 13: 20 1-204.
149. Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourlas PA: A comparative study of serum alphabeta A immunoreactive inhibin and tumor-associated antigens CA 125 and CEA in ovarian cancer. Anticancer Res 1996; 16: 3827-383 1.
150. Bon GG, Verheijen RHM, Zuetenhorst JM, van Kamp GJ, Verstraeten AA, Kenemans P: Mucinlike carcinomaassociated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Gynecol Obstet Invest 1996; 42: 5 8-62.
151. Inaba N, Negishi Y, Fukasawa I, et al: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumour Biol 1995; 16: 345352.